

Paul Savage

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8560906/publications.pdf>

Version: 2024-02-01

11
papers

430
citations

1040056

9
h-index

1372567

10
g-index

11
all docs

11
docs citations

11
times ranked

927
citing authors

#	ARTICLE	IF	CITATIONS
1	ERRÎ± mediates metabolic adaptations driving lapatinib resistance in breast cancer. Nature Communications, 2016, 7, 12156.	12.8	98
2	Epigenetic Switchâ€œInduced Viral Mimicry Evasion in Chemotherapy-Resistant Breast Cancer. Cancer Discovery, 2020, 10, 1312-1329.	9.4	84
3	A Targetable EGFR-Dependent Tumor-Initiating Program in Breast Cancer. Cell Reports, 2017, 21, 1140-1149.	6.4	70
4	Targeting EZH2 reactivates a breast cancer subtype-specific anti-metastatic transcriptional program. Nature Communications, 2018, 9, 2547.	12.8	63
5	Chemogenomic profiling of breast cancer patient-derived xenografts reveals targetable vulnerabilities for difficult-to-treat tumors. Communications Biology, 2020, 3, 310.	4.4	28
6	An ErbB2/c-Src axis links bioenergetics with PRC2 translation to drive epigenetic reprogramming and mammary tumorigenesis. Nature Communications, 2019, 10, 2901.	12.8	24
7	STAT1 potentiates oxidative stress revealing a targetable vulnerability that increases phenformin efficacy in breast cancer. Nature Communications, 2021, 12, 3299.	12.8	24
8	Invasive growth associated with cold-inducible RNA-binding protein expression drives recurrence of surgically resected brain metastases. Neuro-Oncology, 2021, 23, 1470-1480.	1.2	18
9	Co-dependency for MET and FGFR1 in basal triple-negative breast cancers. Npj Breast Cancer, 2021, 7, 36.	5.2	12
10	The effect of the American Joint Committee on Cancer eighth edition on breast cancer staging and prognostication. European Journal of Surgical Oncology, 2019, 45, 1817-1820.	1.0	9
11	p66ShcA potentiates the cytotoxic response of triple negative breast cancers to PARP inhibitors. JCI Insight, 2021, 6, .	5.0	0